Medigene AG
General information
Medigene AG
Lochhamer Str. 11
Planegg
82152 Martinsried, Bavaria
Germany
Contact person: Pamela Keck, Investor Relations / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax: +49 (89) 2000333301
Website: https://www.medigene.com
Lochhamer Str. 11
Planegg
82152 Martinsried, Bavaria
Germany
Contact person: Pamela Keck, Investor Relations / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax: +49 (89) 2000333301
Website: https://www.medigene.com
| Year founded: | 1994 |
| Source of foundation: | Spin-off from company |
| Name of foundation source: | Munich Gene Center |
| No. of employees: | At this location: 64 |
Corporate description / mission:
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. The company's end-to-end technology platform, built on multiple proprietary and exclusive product development and product enhancement technologies, allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. The company's end-to-end technology platform, built on multiple proprietary and exclusive product development and product enhancement technologies, allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2000
Headquarters: Yes
IPO (year): 2000
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 11 |
Special IP situation:
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Technology used:
- TCR-T
- PD1-41BB switch receptor
- Dendritc cells
- TCR-T
- PD1-41BB switch receptor
- Dendritc cells
Financing details
| Market cap. / valuation: | EUR 70.50M |
| Money raised to date: | EUR 61.41M |
Financing details:
Data as of 1 August 2022.
Data as of 1 August 2022.
Collaborations & Clients
Partnering strategy / collaborations:
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant
© 2023 Biotechgate by Venture Valuation